91 related articles for article (PubMed ID: 17888221)
1. Circulating RANKL/OPG in polymyalgia rheumatica.
Pulsatelli L; Dolzani P; Silvestri T; Boiardi L; Salvarani C; Macchioni P; Facchini A; Meliconi R
Clin Exp Rheumatol; 2007; 25(4):621-3. PubMed ID: 17888221
[TBL] [Abstract][Full Text] [Related]
2. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
Pulsatelli L; Dolzani P; Silvestri T; Caraceni P; Facchini A; Ravaglia G; Salvarani C; Melicòni R; Mariani E
Biogerontology; 2004; 5(2):119-27. PubMed ID: 15105586
[TBL] [Abstract][Full Text] [Related]
3. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
4. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
[TBL] [Abstract][Full Text] [Related]
5. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
6. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
[TBL] [Abstract][Full Text] [Related]
7. Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6.
Cutolo M; Straub RH; Foppiani L; Prete C; Pulsatelli L; Sulli A; Boiardi L; Macchioni P; Giusti M; Pizzorni C; Seriolo B; Salvarani C
J Rheumatol; 2002 Apr; 29(4):748-56. PubMed ID: 11950017
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
[TBL] [Abstract][Full Text] [Related]
9. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
10. Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis.
Dovio A; Generali D; Tampellini M; Berruti A; Tedoldi S; Torta M; Bonardi S; Tucci M; Allevi G; Aguggini S; Bottini A; Dogliotti L; Angeli A
Osteoporos Int; 2008 Jan; 19(1):113-7. PubMed ID: 17703272
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.
Raaz-Schrauder D; Schrauder MG; Stumpf C; Lewczuk P; Kilian T; Dietel B; Garlichs CD; Schlundt C; Achenbach S; Klinghammer L
Heart Vessels; 2017 Nov; 32(11):1304-1313. PubMed ID: 28567553
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the relationship between melatonin, hormones of the pituitary-ovarian, -thyroid and -adrenocortical axes, and osteoprotegerin and its ligand sRANKL in girls with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Wołkowska-Pokrywa K; Szapska B
Postepy Hig Med Dosw (Online); 2013 May; 67():433-41. PubMed ID: 23752595
[TBL] [Abstract][Full Text] [Related]
13. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
[TBL] [Abstract][Full Text] [Related]
14. Circulating osteoprotegerin and sRANKL concentrations in the perinatal period at term. The impact of intrauterine growth restriction.
Briana DD; Boutsikou M; Baka S; Hassiakos D; Gourgiotis D; Malamitsi-Puchner A
Neonatology; 2009; 96(2):132-6. PubMed ID: 19365143
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of measuring soluble interleukin-2 receptor in polymyalgia rheumatica.
Gripenberg M; Franzén P; Fröseth B
Scand J Rheumatol; 1995; 24(1):26-8. PubMed ID: 7863274
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
[TBL] [Abstract][Full Text] [Related]
17. Variations in circulating osteoprotegerin and soluble RANKL during diurnal and menstrual cycles in young women.
Shimizu M; Onoe Y; Mikumo M; Miyabara Y; Kuroda T; Yoshikata R; Ishitani K; Okano H; Ohta H
Horm Res; 2009; 71(5):285-9. PubMed ID: 19339793
[TBL] [Abstract][Full Text] [Related]
18. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
Spelling P; Bonfá E; Caparbo VF; Pereira RM
Scand J Rheumatol; 2008; 37(6):439-44. PubMed ID: 18802807
[TBL] [Abstract][Full Text] [Related]
20. The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis.
Gurban CV; Mederle O
Rom J Morphol Embryol; 2011; 52(3 Suppl):1113-9. PubMed ID: 22119834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
